Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

54
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
54
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

42
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
42
Autoimmune Disorders01:29

Autoimmune Disorders

697
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
697
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

48
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
48
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

107
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
107
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

31
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same author

Prevalence and Recovery of Arrhythmia-Induced Cardiomyopathy in Patients With Newly Diagnosed Heart Failure Using a Wearable Defibrillator: A Real-World Cohort Study.

Journal of cardiovascular electrophysiology·2026
Same author

[Orbital pathology, not always caused by endocrine factors].

Praxis·2026
Same author

Current management of eosinophilic granulomatosis with polyangiitis across Europe: insights from a multinational expert survey.

Rheumatology (Oxford, England)·2026
Same author

First profiling of the national Swiss Clinical Quality Management giant cell arteritis and polymyalgia rheumatica registry.

Clinical and experimental rheumatology·2026
Same author

Comparative 1-year outcomes of pentaspline versus circular array pulsed field ablation for pulmonary vein isolation with adjunctive atrial lines.

Heart rhythm·2026

Related Experiment Video

Updated: Sep 22, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K

[ANCA-Associated Vasculitides].

Mihaela Stegert1, Thomas Neumann2, Thomas Daikeler1

  • 1Klinik für Rheumatologie, Universitätsspital Basel.

Therapeutische Umschau. Revue Therapeutique
|May 18, 2022
PubMed
Summary

ANCA-associated vasculitides (AAV) are rare autoimmune diseases. Early recognition and diagnosis are vital for effective immunosuppressive treatment to improve patient outcomes and reduce long-term complications.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • ANCA-associated vasculitides (AAV) are rare autoimmune diseases classified by immunoserological markers (anti-neutrophil cytoplasmic antibodies - ANCA).
  • The main types include microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA), distinguished by clinical, histological, and imaging findings.
  • GPA and EGPA are characterized by granulomatous inflammation in the airways, differentiating them from MPA.

Purpose of the Study:

  • To highlight the importance of recognizing typical symptoms of AAV.
  • To emphasize the critical need for timely diagnosis and immunosuppressive treatment.
  • To discuss recent advancements in AAV therapeutic approaches.

Main Methods:

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K

Related Experiment Videos

Last Updated: Sep 22, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K
  • Classification based on Chapel Hill nomenclature (2012).
  • Diagnosis relies on clinical, histological, and imaging findings.
  • Review of current and emerging treatment strategies.

Main Results:

  • AAV are rare diseases with geographical prevalence variations.
  • Untreated AAV have a poor prognosis regarding organ function and survival.
  • Rituximab has become a key treatment, largely replacing cyclophosphamide.
  • Current therapeutic goals focus on minimizing steroid exposure due to significant side effects.

Conclusions:

  • Timely diagnosis and appropriate immunosuppressive therapy are crucial for managing AAV.
  • Novel treatments like Rituximab offer improved efficacy and potentially fewer side effects.
  • Reducing steroid dependency is a primary objective in AAV treatment to mitigate long-term morbidity.